Icotrokinra (Icotyde) for Psoriasis
Icotrokinra (Icotyde) for Psoriasis
August 3, 2026 (Issue: 1760)
The FDA has approved the oral interleukin (IL)-23 receptor
antagonist icotrokinra (Icotyde – Janssen) for treatment
of moderate to severe plaque psoriasis in patients
≥12 years old who are candidates for systemic treatment or
phototherapy....more
- Drugs for plaque psoriasis. Med Lett Drugs Ther 2024; 66:153.
- A Menter et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for themanagement of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020; 82:1445. doi:10.1016/j.jaad.2020.02.044
- Deucravacitinib (Sotyktu) for plaque psoriasis. Med Lett Drugs Ther 2023; 65:29.
- A Menter et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019; 80:1029. doi:10.1016/j.jaad.2018.11.057
- CA Elmets et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol 2019; 81:775. doi:10.1016/j.jaad.2019.04.042
- LS Gold et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet 2025; 406:1363. doi:10.1016/s0140-6736(25)01576-4
- R Bissonnette et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med 2025; 393:1784. doi:10.1056/nejmoa2504187
- M Gooderham et al. Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid 2025; 4:EVIDoa2500155. doi:10.1056/evidoa2500155
- LK Ferris et al. FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2025; 92:495. doi:10.1016/j.jaad.2024.10.076
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Icotrokinra (Icotyde) for Psoriasis
Article code: 1760b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
